In March 2019, the Health Ministry of India released new guidelines for clinical research. What is the state of pre-market and post-market safety for patients and drugs in India, six months after these new guidelines were announced? Dr. Srikanth Krishnamurthy, a consulting pulmonologist at Sri Bala Medical Centre and Hospital, discusses the pre-market clinical research safety perspective; and Dr. J. Vijay Venkatraman, Managing Director and CEO at Oviya MedSafe, contributes the perspective of post-market drug safety in India.
CTD Speeding Medicines Registration in East Africa
Biosimilar Savings and Their Price: BPCIA Turns Ten
Regulators Promote Reliance as 21st Century Best Practice
Regulatory and Clinical Science Align to Fight COVID-19
DIA Keynote Calls for Expanded COVID-19 Trial Parameters
Impact Philanthropy Accelerating Cures Within Reach
FDA Guidance: Flexibility But No Compromise on Patient Safety
Digital Tools Powering More and Safer Clinical Trials
Latin America's COVID-19 Regulatory Response
Partnerships Essential to SAHPRA Pandemic Response
EFPIA Shares Industry View of EMA Regulatory Framework
Time to Press the Pause Button on Speedy Drug Approvals?
Reach More Patients While Improving Data Quality?
ATMPs May Deliver on Promise of Individualized Medicine
Relevance Will Put Europe on Investment Fast Track
Risk Inherent in Benefits of Drug/Device Products?
EU Business and Data Needs Converge Through Telematics
RIM Accelerating Efficiencies in Regulatory Pathways
Translating Clinical Trials into Clinical Benefit
More Tools & Data Sources: More Insights for RBM?